NICE Demands "Less Biased" Cost Data On Pradaxa For AF
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost-watchdog NICE raises concerns over Boehringer's cost-effectiveness calculations for AF treatment Pradaxa.
You may also be interested in...
Pradaxa Almost Clear Of NICE Hurdle
Boehringer Ingelheim has answered all of NICE's questions on Pradaxa, meaning it is on the brink of being used in the NHS.
Pradaxa Almost Clear Of NICE Hurdle
Boehringer Ingelheim has answered all of NICE's questions on Pradaxa, meaning it is on the brink of being used in the NHS.
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.